1180 related articles for article (PubMed ID: 19608207)
1. 18F9 (4-(3,6-bis (ethoxycarbonyl)-4,5,6,7-tetrahydrothieno (2,3-c) pyridin-2-ylamino)-4-oxobutanoic acid) enhances insulin-mediated glucose uptake in vitro and exhibits antidiabetic activity in vivo in db/db mice.
Anandharajan R; Sayyed SG; Doshi LS; Dixit P; Chandak PG; Dixit AV; Brahma MK; Deshmukh NJ; Gupte R; Damre A; Suthar J; Padigaru M; Sharma SD; Nemmani KV
Metabolism; 2009 Oct; 58(10):1503-16. PubMed ID: 19608207
[TBL] [Abstract][Full Text] [Related]
2. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
[TBL] [Abstract][Full Text] [Related]
3. Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats.
Kramer D; Shapiro R; Adler A; Bush E; Rondinone CM
Metabolism; 2001 Nov; 50(11):1294-300. PubMed ID: 11699047
[TBL] [Abstract][Full Text] [Related]
4. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
[TBL] [Abstract][Full Text] [Related]
5. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
6. KR-62980: a novel peroxisome proliferator-activated receptor gamma agonist with weak adipogenic effects.
Kim KR; Lee JH; Kim SJ; Rhee SD; Jung WH; Yang SD; Kim SS; Ahn JH; Cheon HG
Biochem Pharmacol; 2006 Aug; 72(4):446-54. PubMed ID: 16797489
[TBL] [Abstract][Full Text] [Related]
7. Gly-Ala-Gly-Val-Gly-Tyr, a novel synthetic peptide, improves glucose transport and exerts beneficial lipid metabolic effects in 3T3-L1 adipoctyes.
Kim ED; Kim E; Lee JH; Hyun CK
Eur J Pharmacol; 2011 Jan; 650(1):479-85. PubMed ID: 20951125
[TBL] [Abstract][Full Text] [Related]
8. Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats.
Minoura H; Takeshita S; Kimura C; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Mutoh S
Diabetes Obes Metab; 2007 May; 9(3):369-78. PubMed ID: 17391165
[TBL] [Abstract][Full Text] [Related]
9. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
Díaz-Delfín J; Morales M; Caelles C
Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
[TBL] [Abstract][Full Text] [Related]
10. Bixin regulates mRNA expression involved in adipogenesis and enhances insulin sensitivity in 3T3-L1 adipocytes through PPARgamma activation.
Takahashi N; Goto T; Taimatsu A; Egawa K; Katoh S; Kusudo T; Sakamoto T; Ohyane C; Lee JY; Kim YI; Uemura T; Hirai S; Kawada T
Biochem Biophys Res Commun; 2009 Dec; 390(4):1372-6. PubMed ID: 19891958
[TBL] [Abstract][Full Text] [Related]
11. Functional significance of skeletal muscle adiponectin production, changes in animal models of obesity and diabetes, and regulation by rosiglitazone treatment.
Liu Y; Chewchuk S; Lavigne C; Brûlé S; Pilon G; Houde V; Xu A; Marette A; Sweeney G
Am J Physiol Endocrinol Metab; 2009 Sep; 297(3):E657-64. PubMed ID: 19531641
[TBL] [Abstract][Full Text] [Related]
12. Osthole, a potential antidiabetic agent, alleviates hyperglycemia in db/db mice.
Liang HJ; Suk FM; Wang CK; Hung LF; Liu DZ; Chen NQ; Chen YC; Chang CC; Liang YC
Chem Biol Interact; 2009 Oct; 181(3):309-15. PubMed ID: 19682441
[TBL] [Abstract][Full Text] [Related]
13. Tissue-specific effects of rosiglitazone and exercise in the treatment of lipid-induced insulin resistance.
Lessard SJ; Rivas DA; Chen ZP; Bonen A; Febbraio MA; Reeder DW; Kemp BE; Yaspelkis BB; Hawley JA
Diabetes; 2007 Jul; 56(7):1856-64. PubMed ID: 17440174
[TBL] [Abstract][Full Text] [Related]
14. Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma.
Chakrabarti R; Misra P; Vikramadithyan RK; Premkumar M; Hiriyan J; Datla SR; Damarla RK; Suresh J; Rajagopalan R
Eur J Pharmacol; 2004 May; 491(2-3):195-206. PubMed ID: 15140637
[TBL] [Abstract][Full Text] [Related]
15. Blood glucose-lowering nuclear receptor agonists only partially normalize hepatic gene expression in db/db mice.
Loffler M; Bilban M; Reimers M; Waldhäusl W; Stulnig TM
J Pharmacol Exp Ther; 2006 Feb; 316(2):797-804. PubMed ID: 16260581
[TBL] [Abstract][Full Text] [Related]
16. Kaempferol and quercetin isolated from Euonymus alatus improve glucose uptake of 3T3-L1 cells without adipogenesis activity.
Fang XK; Gao J; Zhu DN
Life Sci; 2008 Mar; 82(11-12):615-22. PubMed ID: 18262572
[TBL] [Abstract][Full Text] [Related]
17. Green tea (-)-epigallocatechin-3-gallate reduces body weight with regulation of multiple genes expression in adipose tissue of diet-induced obese mice.
Lee MS; Kim CT; Kim Y
Ann Nutr Metab; 2009; 54(2):151-7. PubMed ID: 19390166
[TBL] [Abstract][Full Text] [Related]
18. Effect of GCP-02, a PPARalpha/gamma dual activator, on glucose and lipid metabolism in insulin-resistant mice.
Wang ZJ; Liu Q; Li PP; Zou CH; Shen ZF
Eur J Pharmacol; 2008 Feb; 580(1-2):277-83. PubMed ID: 18048028
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614.
Minoura H; Takeshita S; Ita M; Hirosumi J; Mabuchi M; Kawamura I; Nakajima S; Nakayama O; Kayakiri H; Oku T; Ohkubo-Suzuki A; Fukagawa M; Kojo H; Hanioka K; Yamasaki N; Imoto T; Kobayashi Y; Mutoh S
Eur J Pharmacol; 2004 Jun; 494(2-3):273-81. PubMed ID: 15212984
[TBL] [Abstract][Full Text] [Related]
20. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.
Larsen PJ; Lykkegaard K; Larsen LK; Fleckner J; Sauerberg P; Wassermann K; Wulff EM
Eur J Pharmacol; 2008 Oct; 596(1-3):173-9. PubMed ID: 18761337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
